Form 4: Moderna Director Noubar Afeyan Sells Shares Under 10b5-1 Trading Plan

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on May 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 15, 2024, Noubar Afeyan, a director of Moderna, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on February 27, 2023, and amended on November 7, 2023.
• The transactions involved multiple sales at varying prices, ranging from $125.08 to $129.16 per share.
• A total of 14,999 shares were sold directly.
• Following the reported transactions, Afeyan directly owns 1,996,931 shares of Moderna.
• Afeyan also indirectly owns shares through Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The document simply reports the sale of shares under a pre-arranged trading plan, which is a common practice. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Insider sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices, avoiding accusations of trading on non-public information. The market will often scrutinize these sales for any potential implications about the company's future prospects, although pre-planned sales are generally viewed as less informative.

Comparison to Industry Standards

• Comparing Moderna's insider trading activity to other biotechnology companies like Pfizer (PFE) or BioNTech (BNTX) shows similar patterns of executives utilizing 10b5-1 plans for stock sales.
• For example, executives at Pfizer and BioNTech have also used similar plans to manage their stock holdings, aligning with industry best practices for compliance and transparency.
• The volume and frequency of these sales are generally in line with industry norms for companies of Moderna's size and market capitalization.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment in the short term, but the existence of a 10b5-1 plan mitigates concerns about insider information being used for personal gain.

Key Dates